首頁/ZTS

公开研究页

行情来自市场数据接口；下方公司研究基于已核验公开来源，但不等同于实时、个性化的 AI 投资结论。

去工作台分析 ZTS
ZTSNYSE/health care

Zoetis Inc.

$75.39下跌-0,17 (-0,22%)
研究复核截至: 2026年7月12日 上午12:00 [UTC]
研究概览近 3 个月价格投资论点关键催化剂最新财报研究近期新闻数据与研究来源

研究概览

Zoetis Inc. operates in Pharmaceuticals within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Ouverture
75,90
Haut
76,50
Bas
74,53
Capitalisation
31,61 Md
Ratio C/B
12.36
Plus haut sur 52 semaines
--
Dividende
2.810%
Dividende trimestriel
--

近 3 个月价格

這裡展示近 3 個月價格走勢，幫助使用者先理解短期結構，再決定是否進入完整研究工作台。

投资论点

基础情景
Pet owners' focus on longevity and quality of life can sustain medicines, vaccines and diagnostics demand. The base case remains conditional on product safety staying manageable.
多头情景
Pet owners' focus on longevity and quality of life can sustain medicines, vaccines and diagnostics demand. Librela and Solensia can expand treatment of chronic pain in dogs and cats as veterinarian familiarity grows. New vaccines, diagnostics and monoclonal antibodies can extend a differentiated portfolio.
空头情景
Adverse-event concerns or label changes could slow adoption of important companion-animal products. Clinic staffing constraints and affordability pressure can limit visits, diagnoses and treatment starts. Disease outbreaks, commodity economics and regulation can cause abrupt changes in producer demand.
论点失效条件
Reassess the thesis if adverse-event concerns or label changes could slow adoption of important companion-animal products.

关键催化剂

  • Companion-animal spending

    Pet owners' focus on longevity and quality of life can sustain medicines, vaccines and diagnostics demand.

  • Osteoarthritis franchise

    Librela and Solensia can expand treatment of chronic pain in dogs and cats as veterinarian familiarity grows.

  • Animal-health innovation

    New vaccines, diagnostics and monoclonal antibodies can extend a differentiated portfolio.

主要风险

  • Product safety

    Adverse-event concerns or label changes could slow adoption of important companion-animal products.

  • Veterinary capacity

    Clinic staffing constraints and affordability pressure can limit visits, diagnoses and treatment starts.

  • Livestock volatility

    Disease outbreaks, commodity economics and regulation can cause abrupt changes in producer demand.

最新财报研究

Q1 2026

Zoetis's first-quarter 2026 update reflected continued companion-animal demand, growth-product contributions in pain, parasiticides and dermatology and resilient livestock operations across geographies.

估值解读

  • A defensive-growth premium depends on companion-animal innovation remaining durable after launch and safety scrutiny.
  • Portfolio breadth across species and geographies offsets some risk but does not eliminate veterinary-capacity and livestock cycles.

同行比较入口

JNJLLYMRK

近期新闻

24/7 Wall St. · il y a 3 jours

A Dividend Portfolio That Pays For Your Pets

StockStory · il y a 4 jours

2 Value Stocks with Promising Prospects and 1 That Underwhelm

Zacks · il y a 5 jours

ZTS Wins European Commission Approval for New Poultry Disease Vaccine

Bloomberg · il y a 8 jours

Deadly Screwworm’s Leap Into the US Mystifies Health Experts

Stocktwits · il y a 11 jours

Michael Burry Just ‘Shorted Micron’ — Why He Says AI-Fueled Rally Has Pushed MU Into Bubble Territory

StockStory · il y a 12 jours

Branded Pharmaceuticals Stocks Q1 Teardown: Zoetis (NYSE:ZTS) Vs The Rest

数据与研究来源

研究更新: 2026年7月12日 上午12:00 [UTC]
3 个已核验来源
Zoetis Reports First Quarter 2026 ResultsZoetis Inc. · earnings已核验

抓取时间: 2026/7/12 上午12:00:00 [UTC]

发布时间: 2026/5/5 上午12:00:00

查看原始来源
Zoetis Inc. Investor RelationsZoetis Inc. · company已核验

抓取时间: 2026/7/12 上午12:00:00 [UTC]

查看原始来源
Zoetis SEC filings and company factsU.S. Securities and Exchange Commission · filing已核验

抓取时间: 2026/7/12 上午12:00:00 [UTC]

发布时间: 2026/5/5 上午12:00:00

查看原始来源

在工作台中继续研究

保留 ZTS，运行多智能体分析并持续跟踪论点变化。

免费分析 ZTS

探索完整研究體系

每個階段職責明確，並為下一階段留下可追溯的輸出。

研究方法論閱讀市場報告瀏覽股票

继续深挖这只股票

市場分析 Agent

負責先判断价格結構、趋势强弱與交易節奏有没有支持 thesis。

基本面分析 Agent

負責判断公司的业务质量、盈利結構與财务健康度。

新闻分析 Agent

追踪最近发生了什么，以及這些事件是否真的改变 thesis。

風險经理 Agent

負責在風險辩論后给出最终風險等級和执行邊界。